CClinicalTrials.gg
Active, not recruitingNCT05731661AFTERGYNUpdated Jan 15, 2026

Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase

An interventional study of Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse and Delivery of useful information according to support care needs, concerning support care professionals in the city in Long Term Cancer Side Effects, Supportive Care in Cancer and Cancer Survivorship Care Plan, sponsored by Centre Francois Baclesse. Active, not recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Centre Francois Baclesse · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

While the sequelae and toxicities after ovarian and endometrial cancer treatments are well described in the literature, the actual needs of patients for supportive oncology care remain poorly documented. Moreover, there is no data available to estimate the complexity of the oncological support care actions to be implemented.

It is expected that an evaluation of the needs for supportive oncology care and its organization in day hospitalization for supportive oncology care will lead to an improvement in personalized post-cancer follow-up for these patients and to an improvement in their long-term quality of life.

02

Conditions studied

  • Long Term Cancer Side Effects
  • Supportive Care in Cancer
  • Cancer Survivorship Care Plan
  • Advanced Nurse Practitioner
  • Pelvic Gynecological Cancer
03

In context

Lead sponsor

Centre Francois Baclesse is the lead sponsor of 109 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Patient > 18 years old
  • Patient in complete remission after first-line treatment for endometrial or ovarian/fallopian tube/peritoneal cancer
  • Patient having completed her initial treatment; patients with maintenance treatments are eligible
  • Mastery of the French language
  • Patient with a telephone line
  • Patient affiliated to a social security scheme
  • Signature of informed consent before any specific procedure related to the study

Exclusion criteria

Exclusion Criteria:

  • Any associated medical or psychiatric conditions that could compromise the patient's ability to participate in the study
  • Patient with locoregional or metastatic recurrence
  • Patient deprived of liberty, under guardianship or curatorship
  • Simultaneous participation in a therapeutic clinical trial
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
99 participants (estimated)

Study arms

  • Experimental
    Delivery of a Personalized Post-Cancer Plan (PPAC) with a day hospitalization in supportive care

    Other: Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse · Other: Delivery of a personalized post-cancer plan

  • Active comparator
    Delivery of a Personalized Post-Cancer Plan (PPAC) without day hospitalization in supportive care

    Other: Delivery of useful information according to support care needs, concerning support care professionals in the city · Other: Delivery of a personalized post-cancer plan

  • Other
    Observational cohort

    Other: Delivery of a personalized post-cancer plan

Interventions

  • OtherDay hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse

    During this day hospitalization, patients will meet with different specialized professionals depending on the support care needs identified.

  • OtherDelivery of useful information according to support care needs, concerning support care professionals in the city

    Delivery of useful information according to support care needs, concerning support care professionals in the city

  • OtherDelivery of a personalized post-cancer plan

    Delivery of a personalized post-cancer plan

06

What researchers measure

Primary outcomes

  1. Proportion of patients who used at least one of the oncology support services recommended in the Personalized After-Cancer Care Plan within 4 months of receiving the Personalized After-Cancer Care Plan

    Time frame: Up to 4 months

Secondary outcomes

  1. Proportion of patients with sequelae after the initial treatment of their cancer, as well as the type and grade of the sequelae, based on the National Cancer Institute's screening grids (levels 1 and 2) during the consultation with a nurse referent

    Time frame: Up to 4 months

  2. Description of the types of oncological support care needs identified

    Time frame: Up to 4 months

  3. Proportion of patients with identified cancer care needs (at least one cancer care need to be implemented) 4 months after the submission of the Personalized Cancer Care Plan

    Time frame: Up to 4 months

07

Study locations

1 site
  • Centre Francois Baclesse
    Caen, 14076, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05731661
Lead sponsor
Centre Francois Baclesse
Collaborators
Ligue contre le cancer, France
Responsible party
Sponsor
First posted
Feb 16, 2023
Start date
Jan 9, 2023
Primary completion
Nov 20, 2025
Completion
Feb 25, 2027 (estimated)
Last update
Jan 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion